Page 1 of 1

AACR-2016 Clinical Trial Post #2: CFI-400945

Posted: Fri Apr 15, 2016 4:46 pm
by DK37
AACR-2016 Clinical Trial Post #2: CFI-400945

Clinical trial abstracts of the AACR meeting next week were released this afternoon. AACR presents some clinical trial results - the ASCO conference in June presents much more. A lot of eyes will be on the PD1/Avastin/FOLFOX trial results which will be presented on Monday to see if they mention MSS-CRC. Once I hear feedback what was said, I'll post next week on that one.

Today I'll post (3) clinical trial poster abstracts I noticed with CRC data and with currently open trials.

Title: First-in-human phase I trial of the oral PLK4 inhibitor CFI-400945 in patients with advanced solid tumors

Open Trial: https://clinicaltrials.gov/ct2/show/NCT ... 945&rank=1

Mechanism: oral PLK4 inhibitor (targeted agent)

CRC Data: Two patients enrolled at the 48 mg dose level have completed >6 cycles, including a patient with KRAS mutant colorectal cancer who achieved 24% reduction in target lesions and >50% reduction in serum CEA levels.

Side effects: Some chemo-type side effects

Full abstract: http://www.abstractsonline.com/plan/Vie ... 0fb1922267

Re: AACR-2016 Clinical Trial Post #2: CFI-400945

Posted: Fri Apr 15, 2016 11:55 pm
by Nik Colon
Thanks DK :)